

1 **Cost-effectiveness of testing for *Mycoplasma genitalium* among men who have sex with**
2 **men in Australia**

3

4 Jason J. Ong^{1,2,3}, Aaron G. Lim⁴, Catriona S. Bradshaw¹, David Taylor-Robinson⁵, Magnus
5 Unemo^{6,7}, Patrick J. Horner⁴, Peter Vickerman⁴, Lei Zhang^{1,3,8}

6

7 1. Central Clinical School, Monash University, Melbourne 3004, Australia

8 2. Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical
9 Medicine, London WC1E 7HT, United Kingdom

10 3. China-Australia Joint Research Center for Infectious Diseases, School of Public Health,
11 Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, PR China.

12 4. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8
13 1TH, United Kingdom

14 5. Faculty of Medicine, Imperial College London, London SW7 2BX, United Kingdom

15 6. WHO Collaborating Centre for Gonorrhoea and other STIs, Örebro University, Örebro 702
16 81, Sweden

17 7. Institute for Global Health, University College London, London WC1E 6BT, United
18 Kingdom

19 8. Artificial Intelligence and Modelling in Epidemiology Program, Melbourne Sexual Health
20 Centre, Alfred Health, Melbourne 3053, Australia

21

22 **CORRESPONDING AUTHOR:**

23 Jason J. Ong

24 580 Swanston Street

25 Carlton, Victoria 3053, Australia

26 Phone: +613 9341 6200

27 Email: Jason.Ong@monash.edu

28

29 **Running title:** Cost-effectiveness of testing for MG

30 **Word count:** Abstract (236), Main text (2285)

31

32

33 KEY MESSAGES

- 34 • **What is already known on this topic** - *Mycoplasma genitalium* (MG) is a sexually
35 transmitted pathogen with rising antimicrobial resistance.
- 36 • **What this study adds** - This economic evaluation found that testing only
37 symptomatic men who have sex with men (MSM) is the most cost-effective option.
38 When the costs per antibiotic consumed is greater than \$150, any testing for MG is no
39 longer cost-effective.
- 40 • **How this study might affect research, practice or policy** - Among testing strategies
41 for MSM, testing for MG should be restricted to symptomatic men only.

42

43 ABSTRACT

44 Objectives

45 *Mycoplasma genitalium* (MG) disproportionately affects men who have sex with men (MSM).
46 We determined the cost-effectiveness of testing strategies for MG using a healthcare provider
47 perspective.

48 Methods

49 We used inputs from a dynamic transmission model of MG among MSM living in Australia
50 in a decision tree model to evaluate the impact of four testing scenarios on MG incidence: 1)
51 no one tested; 2) symptomatic MSM; 3) symptomatic and high-risk asymptomatic MSM; 4)
52 all MSM. We calculated the incremental cost-effectiveness ratios (ICERs) using a willingness
53 to pay threshold of \$30,000 AUD per QALY gained. We explored the impact of adding an
54 AMR tax (i.e. additional cost per antibiotic consumed) to identify the threshold whereby any
55 testing for MG is no longer cost-effective.

56 Results

57 Testing only symptomatic MSM is the most cost-effective (ICER \$3,677 per QALY gained)
58 approach. Offering testing to all men is dominated (i.e. not recommended because of higher

59 costs and lower QALYs gained compared to other strategies). When the AMR tax was above
60 \$150, any testing for MG was no longer cost-effective.

61 **Conclusion**

62 Testing only symptomatic MSM is the most cost-effective option even when the potential
63 costs associated with AMR are accounted for (up to \$150 additional cost per antibiotic
64 consumed). For pathogens like MG where there are anticipated future costs related to AMR,
65 we recommend models to test the impact of incorporating these costs as they can change the
66 conclusions of cost-effectiveness studies.

67

68 **Keywords:** *Mycoplasma genitalium*, sexually transmitted infection, economic evaluation,
69 antimicrobial resistance, screening

70

71 **INTRODUCTION**

72 *Mycoplasma genitalium* (MG) is a sexually transmitted bacterium that can cause urethritis,
73 cervicitis, endometritis, and pelvic inflammatory disease.¹ A recent systematic review
74 estimates that MG prevalence is 1.3% (95% CI: 1.0-1.8) among the asymptomatic general
75 population in countries with higher Human Development Index (HDI) levels and 3.9% (95%
76 CI: 2.2-6.7) in countries with lower HDI levels.² Of concern, there is a high and rising
77 prevalence of antimicrobial resistance (AMR) in MG globally.³

78

79 Studies in men who have sex with men (MSM) have reported a higher prevalence of MG
80 compared to the general population. For example, in a study of 1001 asymptomatic MSM
81 attending a sexual health clinic in Australia, a prevalence of 9.5% was reported.⁴ However,
82 although MG may cause urethritis and proctitis in MSM,^{1,5} there are no reproductive sequelae
83 as in women.⁶ Consequently, besides treating MG in MSM to alleviate symptoms, there is
84 uncertainty over the benefits of testing for MG in achieving population-level control among
85 MSM.

86

87 Testing asymptomatic individuals for MG is not recommended in the Australian, European,
88 British and US MG management guidelines.⁷⁻¹⁰ This recommendation is currently based on
89 expert opinion. There is a lack of evidence regarding the benefits of testing and treating for
90 MG among asymptomatic individuals, and no cost-effectiveness analysis has been published.

91

92 In this study, we aim to determine the cost-effectiveness of testing for MG using a healthcare
93 provider perspective among MSM living in Australia. We evaluated the cost-effectiveness of
94 testing: 1) no one; 2) only symptomatic MSM (current recommendation); 3) symptomatic and
95 high-risk asymptomatic MSM; 4) all MSM. To account for the potential economic impact of

96 future antimicrobial resistant MG, we also imposed an AMR tax to explore whether this
97 would alter the cost-effectiveness of testing strategies. As the future cost of AMR is complex
98 and uncertain, it is challenging to monetize the direct and indirect consequences of AMR, let
99 alone the costs for developing new antibiotics.¹¹ So, we adopted the approach used by the
100 World Health Organization in the 2021 Guidelines for the management of symptomatic
101 sexually transmitted infections, in their development of the vaginal discharge management
102 algorithm.¹² The AMR tax is applied at the point of antibiotic use, and is a way to incorporate
103 the detrimental effects of AMR into the net present value of the interventions under
104 consideration.¹³

105

106 **METHODS**

107 *Costs*

108 A micro-costing approach was used to identify costs from an Australian healthcare provider
109 perspective for testing and managing MG. The direct medical economic costs of testing and
110 management were collated from the Australian Pharmaceutical Benefits Scheme and data
111 from Melbourne Sexual Health Centre (MSHC), the largest publicly funded sexual health
112 centre in Australia. We accounted for costs related to the medical consultation, tests and
113 antibiotics used. The type of antibiotics used to manage MG infection was based on the
114 current management guidelines at MSHC (Table 1) and the European guidelines¹⁰ (as part of
115 our sensitivity analysis). All costs are reported in Australian dollars (2021 AUD). A gamma
116 distribution was used to characterise the uncertainty for costs (based on +/- 30% of the base-
117 case estimate) in the probabilistic sensitivity analysis.

118

119 The initial cost of testing includes one consultation and one test. If an individual tests positive
120 for MG, he will incur extra costs related to two additional consultations: one consultation for

121 receiving treatment, and one consultation for the test of cure. The antibiotics prescribed will
122 depend on whether the MG strain is macrolide-susceptible or -resistant (Table 2). We
123 evaluated how adding an AMR tax (ranging from 0 to \$200) would affect the cost-
124 effectiveness of testing strategies. There is no single willingness to pay (WTP) threshold in
125 Australia, although there is evidence that medicines are more likely to be recommended for
126 listing with an ICER around \$30,000 than above \$70,000.¹⁴ We used the more conservative
127 WTP of \$30,000 per QALY gained in the analysis, but also provide the probability of being
128 cost-effective across a range of WTP in the cost-effectiveness acceptability curves.

129

130 *Model*

131 We created a decision tree model in TreeAgePro 2021 (TreeAge Software, Williamstown,
132 MA, USA) for four testing scenarios: 1) no one tested; 2) only symptomatic MSM tested (the
133 current recommendation); 3) symptomatic and high-risk asymptomatic MSM tested; 4) all
134 MSM tested. We defined high-risk men as those who reported more than ten sexual partners
135 in the last six months.¹⁵ Figure 1 presents the structure of one testing scenario, which is
136 applied to all four scenarios in the final model. We used this decision tree model to calculate
137 the total cost, total QALYs gained and incremental cost-effectiveness ratio for the four testing
138 scenarios using estimates from a dynamic transmission model of MG among MSM living in
139 Australia that we previously developed.¹⁶ This dynamic transmission model simulated a
140 cohort of MSM who could be infected with wild-type or macrolide-resistant MG. The
141 dynamic model assumes: 1) a closed cohort of MSM (i.e. no transmission between MSM and
142 non-MSM groups, and no births or deaths were incorporated); 2) a treatment effectiveness of
143 92-95% using resistance-guided therapy;¹⁷ 3) no transitions between low- and high-risk men,
144 but sexual mixing can occur between the two populations; 4) the transmission rate is

145 independent of symptom status and the type of MG strain; and 5) 77% of those diagnosed
146 would receive treatment.⁵

147

148 *Model inputs*

149 There are limited data for utility weights related to MG (eTable 1). For men with
150 complications (defined as ongoing symptoms and anxiety associated with the infection), we
151 assumed a utility weight of 0.96, which was based on 3 months with disutility weight of 0.16
152 (based on urethritis).¹⁸ For men receiving a positive MG test with a resistant strain, we
153 assumed 100% had a disutility weight of 0.1 for the first month, 10% with disutility weight of
154 0.1 in the second month, and 2% with disutility weight of 0.1 in the third month. These
155 proportions were based on the clinical experience of sexual health clinicians at MSHC. For
156 men receiving a positive MG test with a wild-type strain, we assumed 100% had a disutility
157 weight of 0.05 for the first month. The probabilities of men having more than 10 partners in
158 the last 6 months, proportion with ongoing symptoms, and proportion of men screened based
159 on symptoms were derived from unpublished data from MSHC.

160

161 *Sensitivity analyses*

162 To examine the impact of parameter uncertainty (eTable 2), we conducted one-way and
163 probabilistic sensitivity analyses and present these as tornado plots and cost-effectiveness
164 acceptability curves, respectively. A Monte Carlo simulation with 100,000 samples was run
165 for the probabilistic sensitivity analysis. In secondary analyses, we tested the effect of a range
166 of AMR tax (\$20 to \$200) on the cost-effectiveness acceptability curves, and to identify the
167 threshold level of the AMR tax where any testing for MG is no longer cost-effective. We also
168 explored a scenario whereby MG testing is conducted in three anatomical sites (eTable 3).

169

170 We report our findings using the Consolidated Health Economic Evaluation Reporting
171 Standards 2022 (CHEERS 2022, Appendix).

172

173 **RESULTS**

174 *Primary cost-effectiveness analysis*

175 Table 3 summarizes the total and incremental cost and QALYs gained in a population of
176 10,000 MSM. It shows that testing all men will always be dominated (i.e. not recommended
177 because of high costs and lower QALYs gained compared to other strategies) regardless of
178 the range of the AMR tax. Testing symptomatic MSM is cost-effective (ICER \$3,677 per
179 QALY gained) compared to no testing. eFigure 1 summarizes the results from the
180 probabilistic sensitivity analyses, demonstrating the probability of being cost-effective at the
181 WTP threshold of \$30,000 was 40.7% for testing symptomatic MSM only.

182

183 *Secondary cost-effectiveness analyses: implementing an AMR tax*

184 eFigures 2 to 6 demonstrates the impact of increasing the AMR tax from \$20 to \$200. The
185 strategy of not testing anyone becomes most cost-effective when the AMR tax is more than
186 \$150.

187

188 *Sensitivity analyses*

189 The univariate sensitivity analysis results are shown in eFigures 7 to 9. The ICER for testing
190 only symptomatic men (current recommendation) compared with no testing was most
191 influenced by the probability of resistant MG in low-risk MSM, the AMR tax and disutility of
192 MG complications. However, the ICERs remain below the willingness to pay threshold,
193 suggesting that testing only symptomatic MSM is cost-effective compared to no testing. The
194 ICER for testing only symptomatic men compared with testing both high-risk asymptomatic

195 men and symptomatic men was most influenced by AMR tax, the probability of wild-type
196 MG in high-risk MSM and probability of wild-type MG. The ICER for testing only
197 symptomatic men compared with testing all MSM was most influenced by the probability of
198 resistant MG in low-risk MSM, the disutility of resistant MG and the AMR tax. However, all
199 ICERs remain cost-saving, suggesting that testing only symptomatic MSM will always be
200 cost-saving compared to testing all MSM. Testing three anatomical sites would increase total
201 costs for each scenario but does not change our conclusions (eTable 3).

202

203 **DISCUSSION**

204 With increasing access to nucleic acid amplification tests for MG, it is important to ensure
205 recommendations to test for MG are informed by robust evidence, including economic
206 evaluations. Thus, our cost-effectiveness analysis provides evidence for the value in money
207 for various testing strategies for an infection that is predominantly asymptomatic in MSM¹⁹,
208 but has rising AMR.^{3,20} Our findings strengthen the evidence base for the current
209 international and national guidelines that recommend testing in symptomatic individuals
210 only.^{7,8,21}

211

212 The current recommendation to test for MG among symptomatic individuals with specific
213 indications is an example of antibiotic stewardship. Overuse of antibiotics has been linked to
214 rising resistance in many pathogens²² and specifically for MG, countries with a higher
215 background of macrolide use has been associated with higher prevalence of macrolide-
216 resistant MG.^{23,24} Thus, restricting antibiotics only for symptomatic MSM minimizes
217 antibiotic consumption in a population that already receives far more antibiotics than the
218 general population.²⁵ Screening asymptomatic men for MSM is problematic on a number of
219 levels. There are no data to suggest asymptomatic MG in MSM is posing a significant risk to

220 health and, due to rising AMR, management of MG is becoming increasingly complex and
221 costly, with challenges in accessing second- or third-line antibiotics outside of specialist
222 sexual health services. Further, we need to consider the harms associated with screening
223 asymptomatic MSM, including the psychological morbidity of being diagnosed with an
224 asymptomatic infection that is unlikely to cause complications among MSM but is
225 increasingly hard to cure and subjects individuals to repeated and often long courses of
226 antibiotics.

227

228 There are increasing reports of the rapid spread of macrolide-resistant MG and the emergence
229 of fluoroquinolone resistance globally.³ Where suboptimal treatment regimens are prescribed
230 (particularly in the context of rising macrolide resistance), offering MG testing might lead to
231 increases in macrolide-resistant MG.¹⁶ This phenomenon is also observed for malaria²⁶ and
232 tuberculosis.²⁷ Subtherapeutic or subinhibitory antibiotic concentrations can promote the
233 development of AMR in not only the target organism but also in other pathogens and
234 commensals.²⁸ Consistent with this, in settings with greater use of macrolides, there is a
235 higher prevalence of macrolide-resistant MG.²⁹ This stresses the urgency of implementing
236 resistance-guided therapy for MG to ensure that the most appropriate antibiotic is selected for
237 eliminating the pathogen.¹⁷

238

239 Since the advent of antibiotics, we have observed that the effectiveness of antibiotics
240 generally wanes over time against most pathogens, particularly when there is over-
241 consumption. Thus, economic models should account for costs related to the development
242 and spread of AMR.^{30,31} Currently, very few models explicitly account for the future costs of
243 AMR.³² Most studies include direct health costs but do not consider non-health perspectives
244 (e.g. societal impact).³² There remains no consensus of how best to capture these costs.

245 Importantly, future costs should also include treating sequelae that arise from untreatable
246 infections (including prolonged hospitalization), the need to use increasingly toxic and costly
247 antibiotics, and the development of new antibiotics to combat infection. While it may not be
248 feasible to accurately capture these specific cost items, the strength of our approach to use an
249 AMR tax would incorporate these components to explicitly demonstrate the impact of AMR
250 on present decision-making. However, a limitation is that we could not disaggregate the
251 direct and indirect costs associated with AMR, nor account for the unmeasured impact on
252 other bacteria and the microbiome in the setting of antibiotic overconsumption.

253

254 The strength of our study is the use of inputs from a dynamic transmission model for MG to
255 evaluate the cost-effectiveness of a variety of testing strategies for MSM. Given the
256 importance of AMR for MG, we also explored the impact of incorporating potential costs of
257 AMR in our models. Our study should be read in light of some limitations. First, our model
258 calculates the incidence at equilibrium with inputs from the transmission dynamic model;
259 thus, we do not have data on how quickly equilibrium is reached. Second, our findings are
260 specifically for MSM and not for heterosexual populations. The disutility from reproductive
261 morbidity associated with MG will need to be accounted for in future studies in heterosexual
262 populations. Third, the AMR profile of MG varies markedly depending on the country and
263 population,³ so we recommend context-specific economic evaluations that also account for
264 locally-derived health and AMR costs. Fourth, there is no consensus on an acceptable
265 threshold for an AMR tax, but we recommend that future models incorporate this as part of
266 their sensitivity analyses given AMR's significant impact on both cost and effectiveness.³³
267 Last, due to absence of data, several model inputs were based on assumptions. Our univariate
268 sensitivity analyses highlight the parameters that would most likely change the ICER of the
269 testing strategy, and thus would benefit from more accurate measurements in future models.

270

271 In conclusion, our study confirms that the current recommendation for MG testing, i.e. testing
272 only symptomatic MSM, is the most cost-effective option in an Australian context. This
273 conclusion remains robust despite uncertainties in multiple parameters, including accounting
274 for future costs of AMR.

275

276

277 **FUNDING**

278 This work was supported by the Australian National Health and Medical Research Council
279 Emerging Leader Fellowship (GNT1193955).

280

281 **COMPETING INTERESTS**

282 All authors declare no conflict of interests.

283

284 **CONTRIBUTORSHIP**

285 JO, LZ conceived the research idea. JO, AGL, PV and LZ constructed the dynamic
286 transmission model and conducted the economic evaluation. JO drafted the first manuscript.

287 All authors contributed to the writing of the paper and approve the final version.

288

289 **PATIENT AND PUBLIC INVOLVEMENT**

290 Patients or the public were not involved in the design, or conduct, or reporting, or
291 dissemination plans of our research.

292

293 **DATA AVAILABILITY**

294 All data produced in the present work are contained in the manuscript.

295

296 **REFERENCES**

- 297 1. Taylor-Robinson D, Jensen JS. Mycoplasma genitalium: from Chrysalis to
298 multicolored butterfly. *Clin Microbiol Rev.* 2011;24(3):498-514.
- 299 2. Baumann L, Cina M, Egli-Gany D, et al. Prevalence of Mycoplasma genitalium in
300 different population groups: systematic review and meta-analysis. *Sex Transm Infect.*
301 2018;94(4):255-262.
- 302 3. Machalek DA, Tao Y, Shilling H, et al. Prevalence of mutations associated with
303 resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a
304 systematic review and meta-analysis. *Lancet Infect Dis.* 2020;20(11):1302-1314.
- 305 4. Read TRH, Murray GL, Danielewski JA, et al. Symptoms, Sites, and Significance of
306 Mycoplasma genitalium in Men Who Have Sex with Men. *Emerg Infect Dis.*
307 2019;25(4):719-727.
- 308 5. Ong JJ, Aung E, Read TRH, et al. Clinical Characteristics of Anorectal Mycoplasma
309 genitalium Infection and Microbial Cure in Men Who Have Sex With Men. *Sex*
310 *Transm Dis.* 2018;45(8):522-526.
- 311 6. Wiesenfeld HC, Manhart LE. Mycoplasma genitalium in Women: Current
312 Knowledge and Research Priorities for This Recently Emerged Pathogen. *J Infect Dis.*
313 2017;216(suppl_2):S389-S395.
- 314 7. Soni S, Horner P, Rayment M, et al. British Association for Sexual Health and HIV
315 national guideline for the management of infection with Mycoplasma genitalium
316 (2018). *Int J STD AIDS.* 2019;30(10):938-950.
- 317 8. Australian sexually transmitted infections management guidelines for use in primary
318 care. The Australian Government Department of Health.
319 <http://www.sti.guidelines.org.au/>. Accessed 21st April 2017.
- 320 9. US Centers for Disease Control and Prevention. Sexually Transmitted Infections
321 Treatment Guidelines, 2021. Mycoplasma genitalium.
322 <https://www.cdc.gov/std/treatment-guidelines/mycoplasmagenitalium.htm>. Accessed
323 23rd November 2021.
- 324 10. Jensen JS, Cusini M, Gomberg M, Moi H, Wilson J, Unemo M. 2021 European
325 guideline on the management of Mycoplasma genitalium infections. *J Eur Acad*
326 *Dermatol Venereol.* 2022.
- 327 11. Naylor NR, Atun R, Zhu N, et al. Estimating the burden of antimicrobial resistance: a
328 systematic literature review. *Antimicrob Resist Infect Control.* 2018;7:58.
- 329 12. World Health Organization. Guidelines for the management of sexually transmitted
330 infections.
331 https://www.who.int/hiv/topics/vct/sw_toolkit/guidelines_management_sti.pdf?ua=1.
332 Accessed 13th Feb 2021.
- 333 13. Shrestha P, Cooper BS, Coast J, et al. Enumerating the economic cost of antimicrobial
334 resistance per antibiotic consumed to inform the evaluation of interventions affecting
335 their use. *Antimicrob Resist Infect Control.* 2018;7:98.
- 336 14. Australian Government Department of Health and Aged Care. The effects of statutory
337 price reductions on the listing of new medicines.
338 <https://www.pbs.gov.au/info/general/working-groups/amwg/amwg-interim-report-attachment-#:~:text=While%20there%20is%20no%20single,with%20an%20ICER%20above%200%2470%2C000>. Accessed 4th August 2022.

- 342 15. STI's in Gay Men Action Group (STIGMA). Sexual transmitted infection testing
343 guidelines for men who have sex with men. STI's in Gay Men Action Group
344 (STIGMA) Web site. 2014. [http://stipu.nsw.gov.au/wp-](http://stipu.nsw.gov.au/wp-content/uploads/STIGMA_Testing_Guidelines_Final_v5.pdf)
345 [content/uploads/STIGMA_Testing_Guidelines_Final_v5.pdf](http://stipu.nsw.gov.au/wp-content/uploads/STIGMA_Testing_Guidelines_Final_v5.pdf). Published 2014.
346 Accessed 31 Dec, 2015.
- 347 16. Ong JJ, Ruan L, Lim AG, et al. Impact of screening on the prevalence and incidence
348 of Mycoplasma genitalium and its macrolide resistance in men who have sex with
349 men living in Australia: A mathematical model. *EClinicalMedicine*. 2021;33:100779.
- 350 17. Read TRH, Fairley CK, Murray GL, et al. Outcomes of Resistance-guided Sequential
351 Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation. *Clin*
352 *Infect Dis*. 2019;68(4):554-560.
- 353 18. Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. *EMBO Mol Med*.
354 2014;6(6):708-720.
- 355 19. Couldwell DL, Jalocon D, Power M, Jeoffreys NJ, Chen SC, Lewis DA. Mycoplasma
356 genitalium: high prevalence of resistance to macrolides and frequent anorectal
357 infection in men who have sex with men in western Sydney. *Sex Transm Infect*.
358 2018;94(6):406-410.
- 359 20. Li Y, Le WJ, Li S, Cao YP, Su XH. Meta-analysis of the efficacy of moxifloxacin in
360 treating Mycoplasma genitalium infection. *Int J STD AIDS*. 2017;28(11):1106-1114.
- 361 21. Jensen JS, Cusini M, Gomberg M, Moi H. 2016 European guideline on Mycoplasma
362 genitalium infections. *J Eur Acad Dermatol Venereol*. 2016;30(10):1650-1656.
- 363 22. Olesen SW, Barnett ML, MacFadden DR, et al. The distribution of antibiotic use and
364 its association with antibiotic resistance. *Elife*. 2018;7.
- 365 23. Kenyon C, Manoharan-Basil SS. Macrolide consumption and resistance in
366 Mycoplasma genitalium. *Lancet Infect Dis*. 2020;20(11):1235-1236.
- 367 24. Kenyon C, Manoharan-Basil SS, Van Dijck C. Is There a Resistance Threshold for
368 Macrolide Consumption? Positive Evidence from an Ecological Analysis of
369 Resistance Data from Streptococcus pneumoniae, Treponema pallidum, and
370 Mycoplasma genitalium. *Microb Drug Resist*. 2021;27(8):1079-1086.
- 371 25. Kenyon C, Baetselier I, Wouters K. Screening for STIs in PrEP cohorts results in high
372 levels of antimicrobial consumption. *Int J STD AIDS*. 2020;31(12):1215-1218.
- 373 26. Wang J, Xu C, Liao FL, Jiang T, Krishna S, Tu Y. Suboptimal dosing triggers
374 artemisinin partner drug resistance. *Lancet Infect Dis*. 2019;19(11):1167-1168.
- 375 27. Kempker RR, Kipiani M, Mirtskhulava V, Tukvadze N, Magee MJ, Blumberg HM.
376 Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among
377 Patients with Multidrug-Resistant Tuberculosis. *Emerg Infect Dis*. 2015;21(6):992-
378 1001.
- 379 28. Viswanathan VK. Off-label abuse of antibiotics by bacteria. *Gut Microbes*.
380 2014;5(1):3-4.
- 381 29. Pitt R, Unemo M, Sonnenberg P, et al. Antimicrobial resistance in Mycoplasma
382 genitalium sampled from the British general population. *Sex Transm Infect*.
383 2020;96(6):464-468.
- 384 30. Niewiadomska AM, Jayabalasingham B, Seidman JC, et al. Population-level
385 mathematical modeling of antimicrobial resistance: a systematic review. *BMC Med*.
386 2019;17(1):81.
- 387 31. Birkegard AC, Halasa T, Toft N, Folkesson A, Graesboll K. Send more data: a
388 systematic review of mathematical models of antimicrobial resistance. *Antimicrob*
389 *Resist Infect Control*. 2018;7:117.
- 390 32. Gandra S, Barter DM, Laxminarayan R. Economic burden of antibiotic resistance:
391 how much do we really know? *Clin Microbiol Infect*. 2014;20(10):973-980.

- 392 33. O'Neill J. Tackling drug resistant infections globally: final report and
393 recommendations. [https://amr-](https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf)
394 [review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf](https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf). Accessed
395 1st Feb 2019.
- 396 34. Australian Government Department of Health. The Pharmaceutical Benefits Scheme.
397 <https://www.pbs.gov.au/pbs/home>. Accessed 20th August 2021.
- 398 35. Medicare Benefits Schedule.
399 [www.health.gov.au/internet/mbsonline/publishing.nsf/Content/Medicare-Benefits-](http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/Medicare-Benefits-Schedule-MBS-1)
400 [Schedule-MBS-1](http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/Medicare-Benefits-Schedule-MBS-1). Accessed 10th July 2014.
- 401 36. Melbourne Sexual Health Centre. Mycoplasma genitalium treatment guidelines.
402 [https://www.mshc.org.au/health-professionals/treatment-guidelines/mycoplasma-](https://www.mshc.org.au/health-professionals/treatment-guidelines/mycoplasma-genitalium-treatment-guidelines)
403 [genitalium-treatment-guidelines](https://www.mshc.org.au/health-professionals/treatment-guidelines/mycoplasma-genitalium-treatment-guidelines). Accessed 24th Feb 2022.
404
- 405

406 **TABLES**

407 **Table 1 The direct health costs of managing a patient diagnosed with macrolide-resistant *Mycoplasma genitalium* using antibiotics recommended at Melbourne**
 408 **Sexual Health Centre, and the European guidelines.**

409

	Initial treatment (100%)	Test of cure	Failed 1 st line (10%)	Test of cure	Failed 2 nd line (2%)	Test of cure
Melbourne Sexual Health Centre						
Antibiotics	Doxycycline 100 mg bd 7 days (\$35.72) followed by Moxifloxacin 400 mg daily for 7 days (\$86.10)		Doxycycline 100 mg bd 7 days (\$35.72) followed by Combination Doxycycline 100 mg bd daily (\$35.72) + Sifloxacin 100 mg bd 7 days (\$145.04)		Combination Doxycycline 100 mg bd 10 days (\$71.44) + Pristinamycin 1 g tds 10 days (\$182.81) OR Minocycline 100 mg 14 days ¹ (\$22.53)	
Consultation	\$38.75	\$38.75	\$38.75	\$38.75	\$38.75	\$38.75
Test		\$39.65		\$39.65		\$39.65
European Guidelines¹⁰						
Antibiotics	Moxifloxacin 400 mg daily for 7 days (\$86.10)		Pristinamycin 1 g four times daily for 10 days (\$182.81)		Minocycline 100 mg two times daily for 14 days	

					(\$22.53)	
Consultation	\$38.75	\$38.75	\$38.75	\$38.75	\$38.75	\$38.75
Test		\$39.65		\$39.65		\$39.65

410 ¹Based on MSHC data, we estimate that 70% would use minocycline

411 **Table 2 Cost (AUD) model input parameters**

Cost parameter	Cost (\$)	Gamma distribution (alpha, lambda)	Reference and assumptions
Doctor's consultation	38.75	11.1, 0.29	PBS ³⁴
Test for MG (including test for macrolide resistance)	39.65	11.1, 0.28	MBS ³⁵ + \$11 for resistance test ¹
Azithromycin 1g stat then 500 mg daily for another 3 days	67.68	-	PBS ³⁴
Doxycycline 100 mg twice daily for 1 week	35.72	-	PBS ³⁴
Moxifloxacin 400 mg daily for 7 days	86.10	-	MSHC ³⁶
Pristinamycin 1g three times a day for 10 days	182.81	-	MSHC ³⁶
Minocycline 100 mg twice daily for 14 days	22.53	-	PBS ³⁴
Sitafloxacin 100 mg twice daily for 7 days	145.04	-	MSHC ³⁶
Cost of antibiotics for treating wild type (MSHC) ²	103.40	11.1, 0.11	PBS ³⁴
Cost of antibiotics for treating wild type (European guidelines)	67.68	11.1, 0.16	¹⁰
Cost of antibiotics for treating resistant MG (MSHC)	147.45	11.1, 0.08	PBS ³⁴
Cost of antibiotics for treating resistant MG ² (European guidelines)	104.83	11.1, 0.11	¹⁰

412 ¹ Discussion with local laboratory (September 2021)

413 ² Based on Doxycycline 100 mg bd 1 week followed by Azithromycin 1 g stat, then 500 mg daily for another 3 days

414 AUD = Australian dollars, MBS = Medicare Benefits Schedule; MG = *Mycoplasma genitalium*; MSHC = Melbourne Sexual Health Centre;

415 PBS = Pharmaceutical Benefits Scheme

416

417 **Table 3 Cost-effectiveness of testing for *Mycoplasma genitalium* among 10,000 men who have sex with**
 418 **men, according to various levels of AMR tax**


	Cost	Incremental cost	QALY	Incremental QALY	ICER
\$0 AMR tax					
No one is tested	0		9,970		
Testing only symptomatic MSM (current recommendation)	11,032	11,032	9,973	3	3,677
Testing symptomatic and high-risk asymptomatic MSM	103,495	92,463	9,975	2	46,232
Testing all MSM	1,417,606	1,314,111	9,961	-14	Dominated
\$20 AMR tax					
No one is tested	0		9,970		
Testing only symptomatic MSM (current recommendation)	15,939	15,939	9,973	3	5,313
Testing symptomatic and high-risk asymptomatic MSM	116,265	100,326	9,975	2	50,163
Testing all MSM	1,463,541	1,347,276	9,961	-14	Dominated
\$50 AMR tax					
No one is tested	0		9,970		
Testing only symptomatic MSM (current recommendation)	23,300	23,300	9,973	3	7,767
Testing symptomatic and high-risk asymptomatic MSM	135,419	112,119	9,975	2	56,060
Testing all MSM	1,532,443	1,397,024	9,961	-14	Dominated

419 AMR = antimicrobial resistance; ICER = incremental cost-effectiveness ratio; MSM = men who have sex with men; QALY = quality-
 420 adjusted life years

421
 422

423 **FIGURES**

424 **Figure 1. Decision tree model for the cost-effectiveness of testing for *Mycoplasma genitalium* among men**
 425 **who have sex with men**



426

427

428 p_{HighRisk} = probability of a men being at high-risk for *Mycoplasma genitalium* (MG)

429 $p_{\text{HR_Resistant}}$ = probability that MG is resistant to macrolides for high-risk MSM

430 $p_{\text{HR_WT}}$ = probability that MG is wild type for high-risk MSM

431 $p_{\text{LR_Resistant}}$ = probability that MG is resistant to macrolides for low-risk MSM

432 $p_{\text{LR_WT}}$ = probability that MG is wild type for low-risk MSM

433 p_{Compl} = probability of complications related to MG

434 # = $1 -$ other rates